CELLULAR HEALTH SCREENING TEST MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Cellular Health Screening Test Market, By Test Type (Telomere Tests, Oxidative Stress Tests, Inflammation Tests, Heavy Metals Tests, Vitamin D Tests, Hormones Tests, and Others), By Sample Type (Blood, Saliva, Urine, and Others), By Product Type (Consumables, Instruments, and Services), By Technology (PCR, Flow cytometry, ELISA, LC-MS, and Others), By End User (Diagnostic Laboratories, Research Institutes, Homecare Settings, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Key Developments:

Product Launches:

In January 2021, Kindbody, a leading fertility and family-building care company, announced the launch of Kind at Home, its consumer products division to support people across their entire reproductive journey, beginning with simple-to-use at-home fertility hormone tests for both women and men. The Kind at Home fertility test kit provides consumers comprehensive information about their fertility status from the convenience of home with personalized recommendations by Kindbody physicians that can be carried to the patient's virtual or in-person clinic appointment.
In November 2021, Allara is a developer of a virtual care platform designed for women struggling with complex, chronic health conditions, starting with polycystic ovary syndrome., announced the launch of its hormonal diagnostic tool. The test is designed to uncover and address a set of hormonal and metabolic markers, providing clarity around a range of symptoms - from physical symptoms like weight gain and acne to “invisible” symptoms like fatigue and anxiety.
In November 2020, OmegaQuant, the leader in omega-3 testing, launched a vitamin D test with a sample collection kit that allows one to test for vitamin D deficiency from home. The simple, safe, and convenient test requires just a finger stick and a couple drops of blood for analysis similar to its range of omega-3 blood tests.

Agreements:

In January 2023, Atomo Diagnostics, an Australia-based diagnostic company, entered into a commercialization agreement with NG Biotech SAS is a developer of rapid point-of-care diagnostics intended to improve decision-making processes in healthcare, to manufacture and distribute rapid blood-based pregnancy tests for both home and professional use in prominent markets. The new pregnancy test combines NG Biotech SAS's manufactured “highly sensitive hCG test assay” and Atomo's integrated Pascal blood test device.
In February 2021, GRAIL, Inc., a healthcare company, announced an agreement with Quest Diagnostics, the leading provider of diagnostic information services, to provide phlebotomy services to support Galleri, GRAIL, Inc's multi-cancer early detection blood test